Floatz logo

Anti-Icos Monoclonal Antibody Medi-570

Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

54 Active assets in the Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type cohort.

Asset / SponsorPhaseRating
Ifosfamide
Shandong Provincial Hospital
Phase 4BBB
DEXAMETHASONE
Ou Bai, MD/PHD
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Eric Jacobsen, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Anti-Icos Monoclonal Antibody Medi-570 is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
mature T-cell and NK-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →